SCHEDULE: Armistice Capital Discloses 5.67% Stake in STAAR Surgical

Armistice Capital, LLC and Steven Boyd have disclosed a 5.67% beneficial ownership stake in STAAR Surgical Co., holding 2,812,000 common shares.

Summary

• Armistice Capital, LLC and Steven Boyd collectively reported beneficial ownership of 2,812,000 common shares of STAAR Surgical Co.
• This ownership represents 5.67% of the company's common stock outstanding.
• The percentage is calculated based on 49,553,035 shares outstanding as of July 30, 2025, as reported in STAAR Surgical's Form 10-Q filed on August 6, 2025.
• Armistice Capital, LLC serves as the investment manager for Armistice Capital Master Fund Ltd., which is the direct holder of the shares, and exercises both voting and investment power over these securities.
• Steven Boyd, as the managing member of Armistice Capital, is also deemed to beneficially own these securities.
• The shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of STAAR Surgical Co.

Sentiment

Score: 7

Explanation: The disclosure of a 5.67% beneficial ownership by Armistice Capital, a known investment firm, suggests a positive view on STAAR Surgical Co.'s valuation or long-term potential. This type of passive investment typically signals confidence without intent to disrupt management.

Positives

• A significant institutional investor, Armistice Capital, has taken a 5.67% stake in STAAR Surgical Co., indicating confidence in the company's prospects.
• The investment is stated to be for ordinary course of business, suggesting a passive, long-term investment rather than an activist position.

Risks

• The filing itself does not detail company-specific operational or financial risks, as it is primarily a disclosure of ownership.
• The investment is passive, meaning the reporting persons do not intend to influence control, which might limit their ability to drive changes if needed.

Future Outlook

Not applicable. This filing is a disclosure of current ownership, not a forward-looking statement from the company.

Industry Context

STAAR Surgical Co. operates in the medical device industry, specifically focusing on implantable lenses for vision correction. A significant stake by an institutional investor like Armistice Capital could signal perceived value or growth potential within the ophthalmology or elective medical procedure sector.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional stake may increase investor confidence and potentially attract more institutional interest, positively impacting share price.
• Company Management: While the investment is passive, a large institutional holder can still exert influence through engagement, though the filing explicitly states no intent to change control.

Key Dates

Recommendation

The filing indicates a significant passive investment by Armistice Capital, suggesting confidence in STAAR Surgical Co. However, a Schedule 13G primarily discloses ownership and does not provide new financial or operational data to warrant a change in fundamental outlook. While the institutional interest is a positive signal, a 'hold' recommendation is prudent as further analysis of the company's financial performance and strategic initiatives would be required for a stronger recommendation.

Keywords

STAAR Surgical, Armistice Capital, Steven Boyd, Schedule 13G, beneficial ownership, common stock, institutional investment, medical devices, ophthalmology, vision care